COVID-19大流行第二年美国癌症筛查情况
研究利用2019和2021年美国国家健康访谈调查数据,评估符合年龄条件人群的乳腺癌、宫颈癌、前列腺癌和结直肠癌筛查率变化。结果显示乳腺癌、宫颈癌和前列腺癌筛查率较疫情前下降,结直肠癌筛查率因粪便检测增加而持平。
要点
- 2021年乳腺癌筛查率从2019年的59.9%降至57.1%(aPR 0.94,95%CI 0.91-0.97)。
- 宫颈癌筛查率从45.3%降至39.0%(aPR 0.85,95%CI 0.82-0.89),前列腺癌从39.5%降至36.3%(aPR 0.9,95%CI 0.84-0.97)。
- 结直肠癌筛查率不变,粪便检测从7.0%升至10.3%(aPR 1.44,95%CI 1.31-1.58),结肠镜从15.5%降至13.8%(aPR 0.88,95%CI 0.83-0.95)。
核心结论
- 在美国COVID-19大流行第二年,符合年龄条件的成年人乳腺癌、宫颈癌和前列腺癌过往一年筛查率仍低于疫情前水平。
- 结直肠癌筛查率保持不变,粪便检测大幅增加,凸显了在卫生系统中断期间居家筛查的作用。
研究设计与样本
- 利用2019年和2021年美国国家健康访谈调查的全国代表性数据,评估符合美国预防服务工作组推荐年龄人群的癌症筛查接受情况。
- 采用复杂调查逻辑回归模型计算2019年和2021年过往一年筛查率及2021年对比2019年的调整患病率比(aPR)及其95%CI。
主要发现
- 乳腺癌筛查率从2019年的59.9%降至2021年的57.1%(aPR 0.94,95%CI 0.91-0.97)。
- 宫颈癌筛查率从45.3%降至39.0%(aPR 0.85,95%CI 0.82-0.89)。
- 前列腺癌筛查率从39.5%降至36.3%(aPR 0.9,95%CI 0.84-0.97)。
- 结直肠癌筛查率保持不变,粪便检测从7.0%升至10.3%(aPR 1.44,95%CI 1.31-1.58),结肠镜从15.5%降至13.8%(aPR 0.88,95%CI 0.83-0.95)。
- 非西班牙裔亚裔人群筛查下降最明显;粪便检测增加在非西班牙裔黑人和西班牙裔人群及低社会经济地位人群中最为显著。
关键数值与推荐
- 乳腺癌筛查年龄为50-74岁女性,宫颈癌为21-65岁未切除子宫女性,前列腺癌为55-69岁男性,结直肠癌为50-75岁男女。
- 筛查率基于美国预防服务工作组推荐。
临床怎么用
- 作者结论强调卫生系统外展和媒体宣传对恢复筛查的重要性。
- 作者指出粪便检测大幅增加凸显了居家筛查在卫生系统中断期间的作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To examine whether cancer screening prevalence in the United States during 2021 has returned to prepandemic levels using nationally representative data. METHODS: Information on receipt of age-eligible screening for breast (women age 50-74 years), cervical (women without a hysterectomy age 21-65 years), prostate (men age 55-69 years), and colorectal cancer (men and women age 50-75 years) according to the US Preventive Services Task Force recommendations was obtained from the 2019 and 2021 National Health Interview Survey. Past-year screening prevalence in 2019 and 2021 and adjusted prevalence ratios (aPRs), 2021 versus 2019, with their 95% CIs were calculated using complex survey logistic regression models. RESULTS: Between 2019 and 2021, past-year screening in the United States decreased from 59.9% to 57.1% (aPR, 0.94; 95% CI, 0.91 to 0.97) for breast cancer, from 45.3% to 39.0% (aPR, 0.85; 95% CI, 0.82 to 0.89) for cervical cancer, and from 39.5% to 36.3% (aPR, 0.9; 95% CI, 0.84 to 0.97) for prostate cancer. Declines were most notable for non-Hispanic Asian persons. Colorectal cancer screening prevalence remained unchanged because an increase in past-year stool testing (from 7.0% to 10.3%; aPR, 1.44; 95% CI, 1.31 to 1.58) offset a decline in colonoscopy (from 15.5% to 13.8%; aPR, 0.88; 95% CI, 0.83 to 0.95). The increase in stool testing was most pronounced in non-Hispanic Black and Hispanic populations and in persons with low socioeconomic status. CONCLUSION: Past-year screening prevalence for breast, cervical, and prostate cancer among age-eligible adults in the United States continued to be lower than prepandemic levels in the second year of the COVID-19 pandemic, reinforcing the importance of return to screening health system outreach and media campaigns. The large increase in stool testing emphasizes the role of home-based screening during health care system disruptions. UNLABELLED: [Media: see text].
引用
- Star J, Bandi P, Siegel RL, et al. Cancer Screening in the United States During the Second Year of the COVID-19 Pandemic. J Clin Oncol. 2023. PMID: 36821800. doi:10.1200/JCO.22.02170
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。